Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Marina Konopleva et al.|Blood|2019Cited by 39
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First RelapseKoji Sasaki, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2019Cited by 13
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2019Cited by 12